Rinvoq XR Shortage: What Providers and Prescribers Need to Know in 2026

Rinvoq XR (upadacitinib) has become one of the most prescribed oral immunomodulators in rheumatology, dermatology, and gastroenterology. With nine FDA-approved indications as of 2025, it is a broadly used agent — but prescribers know firsthand that getting patients to the medication quickly is a significant operational challenge. This guide covers the access landscape for Rinvoq XR in 2026, including prior authorization strategies, specialty pharmacy considerations, and patient assistance resources.

Rinvoq XR Availability Status in 2026

Rinvoq XR is not on the FDA drug shortage list as of 2026. AbbVie continues to manufacture and distribute upadacitinib consistently through its specialty pharmacy network. The drug's wholesale acquisition cost (WAC) is $7,090.41 per 30-day supply as of January 2026. The barrier to access is not supply — it is the complex prior authorization and step therapy ecosystem that governs its use.

Prior Authorization Requirements by Indication

Nearly all commercial plans and Medicare Part D plans require prior authorization for Rinvoq XR. PA requirements typically include:

Rheumatoid Arthritis (RA): Documentation of inadequate response or intolerance to methotrexate AND at least one TNF inhibitor (e.g., adalimumab, etanercept). Most plans require a 3-month trial of the TNF inhibitor. Include DAS28-CRP scores or other validated disease activity measures.

Atopic Dermatitis (AD): Documentation of moderate-to-severe disease, failure of topical therapies (including topical corticosteroids and calcineurin inhibitors), and typically failure of dupilumab (Dupixent) or a biologic. EASI or IGA score documentation strengthens the PA submission.

Ulcerative Colitis / Crohn's Disease: Documentation of moderate-to-severe disease activity, prior biologic failure (TNF inhibitor; anti-integrin or anti-IL-12/23 may be required), baseline labs, and TB screening. As of October 2025, FDA updated labeling to allow Rinvoq XR for UC/CD when TNF blockers are clinically inadvisable after one approved systemic therapy.

Giant Cell Arteritis (GCA): Approved April 2025 at 15 mg once daily. Documentation of confirmed GCA diagnosis (biopsy or imaging). Being the first and only oral JAK inhibitor approved for GCA, PA processes are still evolving — expect payer-specific criteria development through 2026.

Mandatory Pre-Treatment Screening

Before initiating Rinvoq XR, FDA labeling requires the following screening, all of which should be documented in PA submissions:

Tuberculosis (TB) — IGRA or TST; treat latent TB before starting

Viral hepatitis B and C screening

CBC with differential — hold if ANC < 1,000 cells/mm³ or Hgb < 8 g/dL

Liver function tests (LFTs)

Lipid panel (lipids may increase on JAK inhibitors)

Pregnancy test and contraception counseling for women of childbearing potential (embryo-fetal toxicity risk)

Vaccination review — update vaccines (especially herpes zoster) before initiation; live vaccines contraindicated during therapy

Key Drug Interactions Clinicians Must Screen For

Upadacitinib is metabolized primarily by CYP3A4. Key interactions to screen:

Contraindicated: Other JAK inhibitors (tofacitinib, baricitinib, abrocitinib), biologic DMARDs (adalimumab, etanercept, rituximab, abatacept, tocilizumab)

Not recommended: Potent immunosuppressants (azathioprine, cyclosporine); strong CYP3A4 inducers (rifampin — avoid); live vaccines

Use caution: Strong CYP3A4 inhibitors (ketoconazole, voriconazole, tipranavir) — may increase upadacitinib exposure; monitor clinically

Boxed Warning: Risk Communication to Patients

Rinvoq XR carries an FDA Boxed Warning — the agency's most serious warning — for:

Serious infections (including TB, opportunistic infections) — increased risk, potentially fatal

Increased all-cause mortality — in patients 50 years and older with ≥1 cardiovascular risk factor

Malignancies — including lymphoma; increased risk vs. TNF blockers in RA patients who are current/past smokers

Major adverse cardiovascular events (MACE) — MI, stroke, cardiovascular death; risk-benefit assessment required in patients ≥50 with CVD risk factors

Thrombosis — venous and arterial; discontinue immediately and evaluate if symptoms occur

Specialty Pharmacy Workflow Tips

Efficient PA submission is the most impactful thing your office can do to reduce patient access delays:

Include exact dates, dosages, durations, and outcomes for all prior therapies — generic statements like "failed methotrexate" without specifics lead to automatic denials

Attach all required baseline labs and TB screening results with initial submission

Request expedited review (typically 24–72 hours) when clinical urgency exists

Leverage AbbVie's Rinvoq Complete Hub at 1-800-274-6867 — their team can assist with PA initiation, specialty pharmacy routing, and patient assistance enrollment

Helping Patients Who Can't Get Coverage

For patients denied coverage or facing cost barriers, direct them to:

Rinvoq Complete Savings Card — as low as $5/month for commercially insured (max $14,000 savings/year)

myAbbVieAssist — free medication for up to 12 months for uninsured/underinsured patients

Medfinder for Providers — real-time pharmacy inventory checking to help patients locate their dose quickly